

**Table 10. Incidence of gastric ulcers with risendronate and alendronate**

Study	Regimens	Treatment Duration	N	Endpoints	Results
Lanza et al <sup>14</sup>	Risedronate: 5 mg/d Alendronate: 10 mg/d	2 weeks	515	Gastric esophageal and duodenal endoscopy scores.  Incidence of gastric, esophageal, and duodenal ulcers.	Gastric ulcers (> 3 mm): risedronate (4.1%), alendronate (13.2%) (P < 0.001). Mean gastric endoscopy scores for the risedronate were lower than those for the alendronate group at days 8 and 15 (P < 0.001). Mean esophageal and duodenal endoscopy scores were similar in the two groups at days 8 and 15. The study did not evaluate 5 mg alendronate and had a short duration. Proctor & Gamble (Actonel) funded the study.